<SEC-DOCUMENT>0001558370-24-008133.txt : 20240514
<SEC-HEADER>0001558370-24-008133.hdr.sgml : 20240514
<ACCEPTANCE-DATETIME>20240514160615
ACCESSION NUMBER:		0001558370-24-008133
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20240514
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240514
DATE AS OF CHANGE:		20240514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KALA BIO, Inc.
		CENTRAL INDEX KEY:			0001479419
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				270604595
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38150
		FILM NUMBER:		24944263

	BUSINESS ADDRESS:	
		STREET 1:		1167 MASSACHUSETTS AVENUE
		CITY:			ARLINGTON
		STATE:			MA
		ZIP:			02476
		BUSINESS PHONE:		781-996-5252

	MAIL ADDRESS:	
		STREET 1:		1167 MASSACHUSETTS AVENUE
		CITY:			ARLINGTON
		STATE:			MA
		ZIP:			02476

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Kala Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20091223
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>kala-20240514x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.6.2.5 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 5/14/2024 6:41:27 PM -->
<!-- iXBRL Library version: 1.0.8826.24652 -->
<!-- iXBRL Service Job ID: 7920a51d-3e74-480d-a406-390bfcb18532 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:kala="http://www.kalarx.com/20240514" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" name="dei:SecurityExchangeName" id="Hidden_0I0RATgax022cY5wFji6Vw">NASDAQ</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" name="dei:EntityCentralIndexKey" id="Tc_wq0shElf-kC6EhkjxXtEHA_2_1">0001479419</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" name="dei:AmendmentFlag" id="Tc_zXV9_Vazg0-8S9_5RfAdTg_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="kala-20240514.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479419</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-14</xbrli:startDate><xbrli:endDate>2024-05-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_da51e7f7_9153_44c5_b901_031d6bb1bbc6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" name="dei:DocumentType" id="Narr_hZyNDYmlakuw0VNiSp-bJg"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)</b><b style="font-size:12pt;font-weight:bold;"><br/></b><b style="font-size:12pt;font-weight:bold;">of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_u1mzcTbipE-CdYZNKkJMNw"><b style="font-weight:bold;">May 14, 2024</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" name="dei:EntityRegistrantName" id="Narr_YoI-ncHli0qgGcbTQ_U3oQ"><b style="font-weight:bold;">KALA BIO,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Exact Name of Company as Specified in its Charter)</p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_f83a500b_8c5b_4152_82a8_a945bf345b25"></a><a id="Tc_J5AtmRJbR0iG5R5A7pvVxg_2_0"></a><a id="Tc_UpvDEDGf7kKY9RdTxCWufQ_2_1"></a><a id="Tc_UjxlRlpOUE6JddOxIePO-Q_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_u034MhVNCEm0pmj5bBR-Ew_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" name="dei:EntityFileNumber" id="Tc_SHWf6VP6R0iIIRx9xV7e1A_1_1"><b style="font-weight:bold;">001-38150</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" name="dei:EntityTaxIdentificationNumber" id="Tc_ysCmquOip0OX2ktRtqBeEg_1_2"><b style="font-weight:bold;">27-0604595</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:33.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or Other Jurisdiction of Incorporation)</p></td><td style="vertical-align:top;width:33.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Commission File Number)</p></td><td style="vertical-align:top;width:33.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="Narr_pg0jhcfLxE2z7B-t4m5_lQ"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" name="dei:EntityAddressAddressLine1" id="Narr_Yb7aH53uh0WVWQqnoZiPaQ"><b style="font-weight:bold;">1167 Massachusetts Avenue</b></ix:nonNumeric><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" name="dei:EntityAddressCityOrTown" id="Narr_09FiLwiGm0-5GBbQ4zND_g"><b style="font-weight:bold;">Arlington</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" name="dei:EntityAddressStateOrProvince" id="Narr_0QjaeRm_ck-JA2MCr-a68A"><b style="font-weight:bold;">MA</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" name="dei:EntityAddressPostalZipCode" id="Narr_4uuvpfa-40WHdKkcQnAkkw"><b style="font-weight:bold;">02476</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">(Address of Principal Executive Offices) (Zip Code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Company&#8217;s telephone number, including area code: <b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" name="dei:CityAreaCode" id="Narr_jOUOKjGb2Eak_Xdb2QYQ9w"><b style="font-weight:bold;">781</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" name="dei:LocalPhoneNumber" id="Narr_-pVBFPBdJ0qB5mB0Cr_n4A"><b style="font-weight:bold;">996-5252</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_b00eedb9_d838_4df4_9e3d_d66d4ff3bb22"></a><a id="Tc_ydCjmCAV9U2nqiaIkVeTYg_1_1"></a><a id="Tc_VxMLIBa28EecAtsopeRpvg_2_1"></a><a id="Tc_TpDKpYP58UGl9_a31Uu6ng_3_1"></a><a id="Tc_RrIVnIh4GkaaKrtdObX5Gg_4_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1.1pt;"><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:96.3%;margin:0pt;padding:0pt;"><div style="height:1.1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:4.05pt;"><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_XeCEfxH2DE-mthyv74G-hg_1_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr style="height:4.05pt;"><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_-Pn6H5bmMkSqXtNuNm-ZGw_2_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr style="height:4.05pt;"><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_D51lt6jERkCFIJBrrVWnEQ_3_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr style="height:4.05pt;"><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_Q6LHUqO440WbdyJnjkCp7Q_4_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_f9b02db1_b358_4b72_99d7_d9b3ed0c3dc9"></a><a id="Tc_1CxT7HLAFkm39NDQdP9lQg_1_0"></a><a id="Tc_H5GJoDBfmUebBHFE8uvM9Q_1_1"></a><a id="Tc_iQtZb-Mpu0WW3xURtHOAng_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:4pt;"><td style="vertical-align:bottom;width:36.18%;margin:0pt;padding:0pt;"><div style="height:4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:24.09%;margin:0pt;padding:0pt;"><div style="height:4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:39.71%;margin:0pt;padding:0pt;"><div style="height:4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:24.55pt;"><td style="vertical-align:bottom;width:36.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:24.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading symbol(s)</b></p></td><td style="vertical-align:bottom;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr style="height:25pt;"><td style="vertical-align:top;width:36.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" name="dei:Security12bTitle" id="Tc_XQm9A1R3xEWX756pDim1qg_2_0">Common Stock, $0.001 par value per share</ix:nonNumeric></p></td><td style="vertical-align:top;width:24.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" name="dei:TradingSymbol" id="Tc_bfpPDTBnrU2UKTL1wRczuQ_2_1">KALA</ix:nonNumeric></p></td><td style="vertical-align:top;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_0I0RATgax022cY5wFji6Vw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Nasdaq Capital Market</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Emerging growth company&#160;<ix:nonNumeric contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_o7xVvxpHEUCWi6uswc4rYQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_b092d11a_573d_4468_9597_28ce521cf99b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;2.02.&#160;&#160;&#160;Results of Operations and Financial Condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">On May 14, 2024, KALA BIO, Inc. announced its financial results for the quarter ended March 31, 2024 and provided a general business update. The full text of the press release is furnished as Exhibit&#160;99.1 to this Current Report on Form&#160;8-K and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:6pt;background:#ffffff;margin:0pt;">The information in this Current Report on Form&#160;8-K, including Exhibit&#160;99.1 attached hereto, is furnished to comply with Item&#160;2.02 of Form&#160;8-K, and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3b913301_e89b_47f9_a019_2769fda94428"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;9.01.&#160;&#160;Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(d)&#160;&#160;&#160;&#160; Exhibits.</b></p><div style="padding-left:28.8pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:94%;"><tr style="height:3.3pt;"><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:3.3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:3.3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:3.7pt;"><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:3.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:3.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:14.5pt;"><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="kala-20240514xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release of KALA BIO,&#160;Inc. dated May 14, 2024</span></a></p></td></tr><tr style="height:16.75pt;"><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_9c539561_b355_4729_b7de_d702c40513e0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:48.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:51.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">KALA BIO,&#160;INC.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:48.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:48.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 14, 2024</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mary Reumuth</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:48.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Mary Reumuth</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:48.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>kala-20240514xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 5/14/2024 06:41:25 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">-- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">-- Evaluating opportunities to expand KPI-012 development into other corneal diseases, including LSCD and to explore KPI-014 in rare inherited retinal diseases --</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 18pt;"><i style="font-style:italic;">-- Cash resources of $48.5 million as of&#160;March 31, 2024 together with anticipated funding remaining from CIRM award expected to fund operations into 3Q 2025 -- </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARLINGTON, Mass., May 14, 2024 &#8211; </b>KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#8220;In 2024, we are acutely focused on advancing our clinical program for KPI-012 in PCED, a rare, devastating disease caused by an array of underlying etiologies, many of which cannot be treated with currently approved therapeutic options,&#8221; said Mark Iwicki, Chair and Chief Executive Officer of KALA BIO. &#8220;Given its multifactorial mechanism of action and based on clinical data to-date, we believe KPI-012 has the potential to address the multiple impaired corneal healing processes that cause PCED and provide patients a well-tolerated, easily administered and effective therapy. We are targeting topline data from our ongoing Phase 2b CHASE trial by year end which, if successful, could serve as the first of two pivotal trials required to support a BLA submission.&#8221;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Mr. Iwicki continued, &#8220;In parallel, we remain committed to exploring the potential of our platform technology more broadly, as we work to establish KALA as a leader in the emerging field of mesenchymal stem cell secretome therapy. We believe KPI-012 represents a pipeline-in-a-product opportunity and plan to leverage our investigational new drug-enabling activities in PCED to support follow-on indications across a range of corneal diseases, while also exploring the potential for KPI-014, our second asset, across a range of rare, inherited retinal diseases.&#8221; </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">First Quarter and Recent Business Highlights:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">KALA is advancing an innovative pipeline based on its proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA believes the multifactorial mechanism of action of its MSC-S platform technology may enable it to generate products for a range of ocular orphan diseases and is evaluating the potential development of this technology for multiple rare, front- and back-of-the-eye diseases.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">KALA&#8217;s lead product candidate, KPI-012 combines growth factors, protease inhibitors, matrix proteins and neurotrophic factors to potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">KALA is initially developing KPI-012 for the treatment of persistent corneal epithelial defect (PCED), a persistent, non-healing corneal defect or wound that is refractory to conventional treatments which, if left untreated, can lead to significant complications, including infection, corneal perforation/scarring and vision loss. PCED has an estimated incidence of approximately 100,000 patients in the U.S. and we believe represents a sizeable market opportunity; there are currently no U.S. Food and Drug Administration (FDA)-approved prescription products with a broad indication for all underlying etiologies of PCED.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">KALA continues to enroll patients in the CHASE (</font><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">C</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">orneal&#160;</font><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">H</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">ealing&#160;</font><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">A</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">fter&#160;</font><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">SE</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">cretome therapy) Phase 2b clinical trial evaluating KPI-012 for the treatment of PCED, and are targeting the announcement of topline data by year-end 2024. Contingent on positive results and subject to discussion with regulatory authorities, the Company believes the CHASE Phase 2b trial could potentially serve as the first of two pivotal studies to support the submission of a Biologics License Application (BLA) to the FDA.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">KALA is also exploring the potential of KPI-012 for additional rare, front-of-the-eye diseases, including Limbal Stem Cell Deficiency (LSCD) and other corneal diseases. LSCD is characterized by the loss or deficiency of limbal epithelial stem cells, which can result in recurrent epithelial breakdown, neovascularization, </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">conjunctivalization, inflammation and other sequalae that can lead to loss of corneal clarity and vision impairment. Like PCED, LSCD represents a substantial market opportunity, with an estimated incidence of 100,000 patients in the U.S.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">KPI-014, KALA&#8217;s preclinical program to evaluate the utility of its MSC-S platform for inherited retinal degenerative diseases, contains neurotrophic factors, growth factors, anti-inflammatory or immune-modulatory factors and antioxidant inhibitors with the potential to protect and preserve retinal cell function. Secretomes have demonstrated a neuroprotective effect in both <i style="font-style:italic;">in vitro</i> and <i style="font-style:italic;">in vivo</i> models of retinal degeneration. KALA believes KPI-014 could offer a gene-agnostic approach for the treatment of rare inherited retinal diseases and has initiated preclinical studies to evaluate the utility of KPI-014 for conditions such as Retinitis Pigmentosa and Stargardt Disease. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial Results:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Position: </b>As of March 31, 2024, KALA had cash and cash equivalents of $48.5<font style="color:#ff0000;"> </font>million, compared to $50.9<font style="color:#ff0000;"> </font>million as of December 31, 2023. This decrease reflects cash used in operations, partially offset by gross proceeds of $8.6 million received from KALA&#8217;s March 2024 private placement financing. Based on its current plans, KALA anticipates that its cash resources as of March 31, 2024, together with anticipated funding under the CIRM award, will enable it to fund operations into the third quarter of 2025.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">First Quarter 2024 Financial Results:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">G&amp;A Expenses:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> For the quarter ended March 31, 2024, general and administrative (G&amp;A) expenses were $5.4 million, compared to $6.0 million for the same period in 2023. The decrease was primarily due to a decrease in administrative and professional service fees, partially offset by an increase in stock-based compensation costs and employee related costs. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">R&amp;D Expenses:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> For the quarter ended March 31, 2024, research and development (R&amp;D) expenses were $6.4 million, compared to $4.0 million for the same period in 2023. The increase was primarily due to an increase in KPI-012 development costs and employee-related costs, as we advance the clinical development of KPI-012, and an increase in other research and development costs.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Gain on Fair Value Remeasurement of Deferred Purchase Consideration</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">: For the quarter ended March 31, 2024, </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">there was no gain or loss on fair value remeasurement of deferred purchase consideration, in connection with the acquisition of Combangio. For the same period in 2023, there was a gain of $0.2 million.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Loss on Fair Value Remeasurement of Contingent Consideration: </b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">For the quarter ended March 31, 2024, the loss on fair value remeasurement of continent consideration, in connection with the Combangio acquisition, was $0.2 million, compared to a loss of $1.8 million for the same period in 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Operating Loss: </b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">For the quarter ended March 31, 2024, loss from operations was $11.9</font><font style="color:#ff0000;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">million, compared to $11.7 million for the same period in 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Net Loss:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> For the quarter ended March 31, 2024, net loss was $11.8 million, or $4.20</font><font style="color:#ff0000;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">per share, compared to a net loss of $14.5 million, or $6.99 per share, for the same period in 2023. The weighted average number of shares used to calculate net loss per share was 2.8 million for the quarter ended March 31, 2024, and 2.1 million for the quarter ended March 31, 2023.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">About KALA BIO, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA&#8217;s biologics-based investigational therapies utilize KALA&#8217;s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA&#8217;s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA, please visit www.kalarx.com.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Forward Looking Statements: </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. Any statements in this press release about KALA&#8217;s future expectations, plans and prospects, including but not limited to statements about KALA&#8217;s expectations with respect to potential advantages of KPI-012 and its MSC-S platform; the clinical utility of KPI-012 for PCED; anticipated timelines to report topline data for the CHASE Phase 2b clinical trial of KPI-012; KALA&#8217;s belief that the Chase Phase 2b trial could serve as the first of two pivotal trials required to support the submission of a BLA to the FDA; KALA&#8217;s plans to pursue research and development of KPI-012 and its MSC-S platform for other indications; expectations about the potential benefits and future operation of the CIRM award; KALA&#8217;s ability to achieve the specified milestones and obtain the full funding under the CIRM award; the sufficiency of KALA&#8217;s existing cash resources for the period anticipated; and other statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: KALA&#8217;s ability to comply with the requirements under the CIRM award; uncertainties inherent in the initiation and conduct of preclinical studies and clinical trials; uncertainties regarding availability and timing of data from clinical trials; whether results of early clinical trials or trials in different disease indications will be indicative of the results of ongoing or future trials; whether results of the Phase 1b clinical trial of KPI-012 will be indicative of results for any future clinical trials and studies of KPI-012, including the CHASE Phase 2b clinical trial; whether interim data from a clinical trial will be predictive of the results of the trial; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; KALA&#8217;s ability to retain and hire key personnel; KALA&#8217;s ability to comply with the covenants under its loan agreement, including the requirement that its common stock continue to be listed on The Nasdaq Stock Market; the sufficiency of cash resources and need for additional financing and other important factors, any of which could cause KALA&#8217;s actual results to differ from those contained in the forward-looking statements, discussed in the &#8220;Risk Factors&#8221; section of KALA&#8217;s Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and other filings KALA makes with the Securities and Exchange Commission. These forward-looking statements represent KALA&#8217;s views as of the date of this press release and should not be relied upon as representing KALA&#8217;s views as of any date subsequent to the date hereof. KALA does not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Financial Tables:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">KALA BIO, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance Sheet Data</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:58.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:top;width:58.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:top;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:middle;width:58.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:top;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 48,478</font></p></td><td style="vertical-align:bottom;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 50,895</font></p></td></tr><tr><td style="vertical-align:middle;width:58.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Total assets</p></td><td style="vertical-align:top;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 53,033</font></p></td><td style="vertical-align:bottom;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 55,949</font></p></td></tr><tr><td style="vertical-align:middle;width:58.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Working capital&#160;<sup style="font-size:6.75pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:top;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 38,208</font></p></td><td style="vertical-align:bottom;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 44,524</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Long&#8209;term debt, net of discounts</p></td><td style="vertical-align:top;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 28,510</font></p></td><td style="vertical-align:bottom;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 34,190</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Other long&#8209;term liabilities</p></td><td style="vertical-align:top;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 5,983</font></p></td><td style="vertical-align:bottom;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 5,909</font></p></td></tr><tr><td style="vertical-align:middle;width:58.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:top;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 6,661</font></p></td><td style="vertical-align:bottom;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 7,504</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">(1) The Company defines working capital as current assets less current liabilities. See the Company&#8217;s consolidated financial statements for further information regarding its current assets and current liabilities.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">KALA BIO, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statement of Operations</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share data)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:24.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:top;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:24.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td></tr><tr><td style="vertical-align:top;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Costs and expenses:</p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 5,422</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 6,030</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 6,351</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 4,036</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Gain on fair value remeasurement of deferred purchase consideration</p></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (230)</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Loss on fair value remeasurement of contingent consideration</p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 158</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,847</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 11,931</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 11,683</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (11,931)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (11,683)</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 504</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 675</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,455)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,474)</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Grant income</p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,075</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Other (expense) income, net</p></td><td style="vertical-align:bottom;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,973)</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (11,807)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (14,455)</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Net loss per share attributable to common stockholders&#8212;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (4.20)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (6.99)</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Weighted average shares outstanding&#8212;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,813,210</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,069,186</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Investor Contact:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Hannah Deresiewicz</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">hannah.deresiewicz@sternir.com</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">212-362-1200</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>kala-20240514.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/14/2024 6:41:32 PM-->
<!--Modified on: 5/14/2024 6:41:32 PM-->
<xsd:schema targetNamespace="http://www.kalarx.com/20240514" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:kala="http://www.kalarx.com/20240514">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="kala-20240514_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="kala-20240514_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>kala-20240514_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/14/2024 6:41:32 PM-->
<!--Modified on: 5/14/2024 6:41:32 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>kala-20240514_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/14/2024 6:41:32 PM-->
<!--Modified on: 5/14/2024 6:41:32 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="kala-20240514.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638513088928092584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638513088928092584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638513088928092584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638513088928092584" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638513088928092584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638513088928092584" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638513088928092584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638513088928092584" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638513088928092584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638513088928092584" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638513088928102963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638513088928102963" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638513088928102963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638513088928102963" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638513088928102963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638513088928102963" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638513088928102963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638513088928102963" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638513088928102963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638513088928102963" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638513088928102963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638513088928102963" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638513088928102963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638513088928102963" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638513088928102963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638513088928102963" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638513088928102963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638513088928102963" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638513088928102963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638513088928102963" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638513088928102963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638513088928102963" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638513088928112557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638513088928112557" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638513088928112557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638513088928112557" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638513088928112557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638513088928112557" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638513088928112557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638513088928112557" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638513088928112557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638513088928112557" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638513088928112557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638513088928112557" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140689994403840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 14, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 14,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KALA BIO,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-0604595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1167 Massachusetts Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Arlington<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">996-5252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KALA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001479419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M$)?M!&R\G^)6_19KV&6(%:'NC\N?R(('!=3;MI4)5S+U"4O:0HO@\QGYWKF
M+0C)F23O+"DXR6&X*F(2PW:;-<#%3?M-LM"4WV*;+D5K\74(F+T(1M(8OHN;
M\SYBY.XCB%BVYD<W1QU"S_[BUO\-8SHX&)SD]'<IEVL3I5] 04?&07*6M>:V
M0["KWMS&Z%W<IW=H-S 7)!CM#*;!!WG@[5"XE ,%Y@U&'AUA9(WSN[AI^S _
MPW*.WB=LW<J#"QP-DGUP!C7G^2=FTJ)(PE<@Y%P,P+=E=42N&EKDY;%T*30<
M<LO;B#,P#/,"_+X20N\;YJ1;_Z-B^B]02P,$%     @ QH"N6)^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ QH"N6 =!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " #&@*Y89&&KJ>X    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " #&@*Y8F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,:
MKE@5R]CZ3P0  +00   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " #&@*Y8GZ ;\+$"  #B#   #0
M        @ &2#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,: KEB7BKL<
MP    !,"   +              "  6X/  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( ,: KE@<.&7J/P$  #P"   /              "  5<0  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " #&@*Y8)!Z;HJT   #X 0  &@
M    @ '#$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" #&@*Y899!YDAD!  #/ P  $P              @ &H$@  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"  #R$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="kala-20240514x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kalarx.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName -  kala-20240514x8k.htm 9</Log>
  </Logs>
  <InputFiles>
    <File>kala-20240514.xsd</File>
    <File>kala-20240514_lab.xml</File>
    <File>kala-20240514_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="kala-20240514x8k.htm">kala-20240514x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "kala-20240514x8k.htm": {
   "nsprefix": "kala",
   "nsuri": "http://www.kalarx.com/20240514",
   "dts": {
    "schema": {
     "local": [
      "kala-20240514.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "kala-20240514_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kala-20240514_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "kala-20240514x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kala-20240514x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kala-20240514x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-24-008133-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-008133-xbrl.zip
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M<03H7BB=0334."1ZI! 6GL,$>CK=D%5WJ!9I%;@M75WF9#P>1PZM(V6D6Q2
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M1F@UG%5YCP0S\WRG#D"ZPQ-I;A7-!NZ+PR<VIFNR;QH*RE.!\G5[6B1?9*<
MI";M6^$HK>6%79HWC6*RJWAB0T:?,0G,^U.C_%2@-#2J);.D/04\39'?BM%\
M]ZE&:!K4(8VY'_V%EY6W40;QJ4"J;5*+:$%Y"H#J [\5GJD["/NF;HODHGW+
MD&_ L52V&$!=(_G7?#LU2R'31JR+57(EEFY-422_S(^&<TK,'X-K)!;39&I(
M$56N6TJ5,69=LA)#2!R;NQO^DV'.$>G3Q6)%LGOQ6-.M26<Q9Y6M*=BT(DN)
MJ\Y:%[O,%8JV#: WHA$.,,=D]B@VC@S[NIZU(HNA,S>EB'NML!2WBJ!U67NQ
M!.79 &A#AB3<2+QQR9,8\IDP]C2=:J^EE6*+P=O?I +0K+04Q ,"UP526#O!
MCC>DYI"X-X_F0QRO$/LN0'6GG ZFQH8-L+[2GP:RYMAO!FXZ1-/\CE"P$ON'
MK=>9C#&/=+>Y&HG%?)H:RJ_>I;JE_!ECUN4M<0$Z!:_SR^174/X-(#9FOGS$
M?[1=3*BNU7+=8KBTK2BR"D5+L=)GK,U4Z@:I78.KU?TFF(O(R/#,ET%F,5A5
MC957KEV-I9A51JU][Y&9@G)M]IFO^P5B,T'[;XRN^5QL#I8^V1H_$3>I+6;P
M@#:+7U-HI982>4CB([^H4.:0ND-FWQB@?;&+9'[T(/:/F]^1&<W7.NNA-+16
MQ+$DLAI$4]8C$<QL(?$%8=P ?+?B[B64=S"?(G^F:;A<MQ@V;2L*LD+14KCT
M&>M"E;N!M-M%Z<I]&7D@CN1?P&8O96??_ =02P,$%     @ QH"N6.71*!%S
M!   [R4  !4   !K86QA+3(P,C0P-3$T7W!R92YX;6S56EV/VC@4?5]I_X,W
M^YQOH("&5@R=KM .'310M=J7RB0&K"9VY)@!_OW:(69)2""L=D/S B$^OC[W
M'./X)GGXL L#\(98C"D9:+9A:0 1C_J8K ;:)M9A[&&L?7C_ZR\/O^GZM\?7
M9^!3;Q,BPH''$.3(!UO,UV!.HP@2,$&,X2  CPS[*P2 ;1D=PS':0-?3&(\P
M%GTH 4DPQ["/+:,T'B5]T#;MENE83@MT^BV[[SI@.CD")X+?$E]%!IC\Z,N/
MA1@2B$1)W-_%>*"M.8_ZIKG=;HVM:U"V$OTMV_PV>9YY:Q1"'9.80^(A#0A\
M/TY./E,/\D2ED^Z[!0M4 -<\CE6*D+]T!=/E*=UV=-<V=K&OI11E<X5!%%RV
MX@OXDUP.^+/XJ09VK]<SDU9-J ?  Z,!>D5+D)SK\WV$!EJ,PRB0L9)S:X:6
M ^T'#* N';#:=DMF\OO'=(JH[R'QGPC'?#\F2\K"1$<-R/A?7L<9+C(6VQD>
M#4W9;%:+E&1623/SD%K$4"RB)=V?16.:CQSROZ!S(AC:<41\Y!_/8B['L"RK
M9P$=J$"GAY#XX! 5_+LLDQQ%E@'U,EP".84IR[HGP\4B7A(K1IZQHF^FC[#\
M3[GR0%KK)K:*']]'5*P6PT7,&?2XBA3 !0H&6J[-_#]Y*+7F(F*.1K[Y>\?M
MMFW7ZG9[3M?J.>UNZX3<Z508LBQ1R#P56QR>S8ZL_"G"C" 3\71OC8.CZTM&
MPS-]TI%H1<:4^8B)-5H#FUCPH)%D#(.:=)XBAJF8[/Y'L49?$#R#:Y;RUZFG
M%CCU6G!8"S[A 'W>A O$"M3/0YHA?"76J>;N/31_12LLJ1/^&89%L[X(UB3M
M*S!/]6_=0_^QV(JRB+)$K9D0#8WHAG"V'U&_W(Z+O9KDSNV)I&:U[V'6'.[&
MODA6;,T/.^4KJU4)/I.7;3F]COO3&G1+"JDUG7M8,_1]H5N<?HD-+[)+;2G
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MYPJ1-YIA75Q+'DB["A.J_/R:F$Y4"WA![%2LAM-B$RC; 048CG3]'OZ"=3-
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M2CKI*V<&/T:1Y[[Y+U!+ 0(4 Q0    ( ,: KECDKX<5<@,  $H,   1
M          "  0    !K86QA+3(P,C0P-3$T+GAS9%!+ 0(4 Q0    ( ,:
MKEA*C.UI:@4  .X[   5              "  :$#  !K86QA+3(P,C0P-3$T
M7VQA8BYX;6Q02P$"% ,4    " #&@*Y8Y=$H$7,$  #O)0  %0
M    @ $^"0  :V%L82TR,#(T,#4Q-%]P<F4N>&UL4$L! A0#%     @ QH"N
M6,?L06]<%   X'\  !0              ( !Y T  &MA;&$M,C R-# U,31X
M.&LN:'1M4$L! A0#%     @ QH"N6(7*-$="'@  #40! !@
M ( !<B(  &MA;&$M,C R-# U,31X97@Y.60Q+FAT;5!+!08     !0 % $T!
(  #J0      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>kala-20240514x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="kala-20240514.xsd" xlink:type="simple"/>
    <context id="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479419</identifier>
        </entity>
        <period>
            <startDate>2024-05-14</startDate>
            <endDate>2024-05-14</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Hidden_0I0RATgax022cY5wFji6Vw">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCentralIndexKey
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Tc_wq0shElf-kC6EhkjxXtEHA_2_1">0001479419</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Tc_zXV9_Vazg0-8S9_5RfAdTg_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Narr_hZyNDYmlakuw0VNiSp-bJg">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Narr_u1mzcTbipE-CdYZNKkJMNw">2024-05-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Narr_YoI-ncHli0qgGcbTQ_U3oQ">KALA BIO,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Tc_u034MhVNCEm0pmj5bBR-Ew_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Tc_SHWf6VP6R0iIIRx9xV7e1A_1_1">001-38150</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Tc_ysCmquOip0OX2ktRtqBeEg_1_2">27-0604595</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Narr_Yb7aH53uh0WVWQqnoZiPaQ">1167 Massachusetts Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Narr_09FiLwiGm0-5GBbQ4zND_g">Arlington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Narr_0QjaeRm_ck-JA2MCr-a68A">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Narr_4uuvpfa-40WHdKkcQnAkkw">02476</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Narr_jOUOKjGb2Eak_Xdb2QYQ9w">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Narr_-pVBFPBdJ0qB5mB0Cr_n4A">996-5252</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Tc_XeCEfxH2DE-mthyv74G-hg_1_0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Tc_-Pn6H5bmMkSqXtNuNm-ZGw_2_0">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Tc_D51lt6jERkCFIJBrrVWnEQ_3_0">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Tc_Q6LHUqO440WbdyJnjkCp7Q_4_0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Tc_XQm9A1R3xEWX756pDim1qg_2_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Tc_bfpPDTBnrU2UKTL1wRczuQ_2_1">KALA</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_5_14_2024_To_5_14_2024_L3x_-VehBUW1aROfvSnhIA"
      id="Narr_o7xVvxpHEUCWi6uswc4rYQ">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
